FDA issued a Warning Letter to BioReliance Corporation on 1/5/2009 for a previous inspection.
483 BioReliance May 2014

483 BioReliance May 2014

Toyin Oladimeji FDA, Nebil Oumer FDA$119.00 - Available Now

FDA investigators audited the BioReliance - Rockville, MD, United States facility and issued inspectional observations (via FDA 483) on 14 May 2014.

Product details

  • Category: Human Drugs
  • Inspection end: 14 May 2014
  • Location: Rockville, United States
  • FEI: 1122041
Add To Cart